Zachary Kanter

Zachary Kanter, known as Zak, is an operator-investor at Roivant Sciences, specializing in venture creation, investments, and growth within biotech, health tech, and digital health.

Roivant Sciences, a prominent pharma-tech company he is associated with, boasts a substantial pipeline of 45+ investigational drugs and has secured over $5 billion in capital from notable investors like the SoftBank Vision Fund and Viking Global.

Zak's educational background includes earning a Master's degree in Business Administration from the London Business School, completing the HMX Pro Certificate Program at Harvard Medical School, and pursuing studies at EMBA-Global Asia with a focus on business and management.

Moreover, he holds a Bachelor's degree in Biochemical Engineering with a specialization in Bioprocessing and Management from UCL, complemented by coursework in Law and Philosophy at Yeshivat Har Etzion.

Before his current role at Roivant, Zak served in various capacities such as Product Management & Operations Lead at Alyvant, Inc., Business Development & Partnerships Lead at VantAI, and Strategic Finance & Investor Relations at Datavant.

He has also been actively involved in academia, having been a Merit Scholar at the London Business School and a teaching faculty member at the UCL School of Management, where he shared his expertise with students.

Outside of his professional endeavors, Zak extends his support to child health non-profits and digital health startups, offering guidance on strategy, business development, and fundraising initiatives.

To connect with him, you can reach out via email at zakanter123@gmail.com.